Choice of therapy for iron deficiency anemia associated with helicobacter pylori

Abstract

Aim: in a comparative aspect, to choose the most effective method for the treatment of iron deficiency anemia associated with Helicobacter pylori. Material and methods: The study was conducted in 90 patients diagnosed with iron deficiency anemia with complaints of the gastrointestinal tract, which were divided into two groups. The first group consisted of 60 patients who initially received antihelicobacter complex treatment (amoxiclav + clarithromycin + ezemeprozole), and then antianemic drugs (first by injection, and then in tablets for 3 months, depending on the severity of the disease). The control group consisted of 30 patients, 10 each with mild, moderate and severe anemia, who received only antianemic treatment. Results. In the main group, after antihelicobacter and subsequent antianemic treatment, all indicators changed in a highly significant (p<0.001) positive direction. Unlike the main group, in the control group, which received only antianemic drugs, the hemoglobin index significantly increased from 65.2±1.72 g/l to 91±1.42 g/l, but the values did not reach the normal level. Serum levels of iron and ferritin also decreased from 2.25 ± 0.15 mmol/l to 9.22 ± 0.15 mmol/l and from 3.79 ± 0.45 µg/l to 55.14 ± 0, respectively. The determined indicators confirm that anemia has not been eliminated. In addition, positive and significant changes in the level of transferrin saturation were observed, however, the level of iron saturation did not reach the norm, being less than 20%. Despite the decrease in soluble transferrin from 6.06±1.03 g/l to 5.86±1.035 g/l, the determined indicator indicates the persistence of the state of iron deficiency in patients in the control group.